The future of deep venous thrombosis and post-thrombotic syndrome in 2020

Phlebology

Volumn 27, Issue SUPPL. 1, 2012, Pages 95-102

  Comerota, Anthony J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TOLEDO HOSPITAL   (United States)

Author keywords

Catheter; DVT; Endovenectomy; Thrombectomy; Thrombolysis

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 11A INHIBITOR; BLOOD CLOTTING INHIBITOR; DABIGATRAN; ENOXAPARIN; GADOFOSVESET; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ARTIFICIAL EMBOLISM; BLEEDING; BLOOD VOLUME; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; COMPUTED TOMOGRAPHY VENOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FILTER; HEMATOMA; HIGH RISK PATIENT; HUMAN; INFERIOR CAVA VEIN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LIVER DYSFUNCTION; LONG TERM SURVIVAL; LUNG EMBOLISM; MECHANICAL THROMBECTOMY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; POSTOPERATIVE THROMBOSIS; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; THROMBECTOMY; THROMBOSIS PREVENTION; TREATMENT DURATION; VASCULAR PATENCY; VEIN THROMBECTOMY; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

FORECASTING; HUMANS; POSTTHROMBOTIC SYNDROME; PULMONARY EMBOLISM; RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS; VENOUS THROMBOSIS;

EID: 84856796198     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1258/phleb.2011.012S08     Document Type: Review

References (33)

1. Knudson MM, Morabito D, Paiement GD, et al. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma 1996;41:446-59
2. Griffin M, Kakkos SK, Geroulakos G, et al. Comparison of three intermittent pneumatic compression systems in patients with varicose veins: a haemodynamic study. Int Angiol 2007;26:158-64
3. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 2008;372:31-9
4. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86
5. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-80
6. Hull RD, Schellong SM, Tapson VF, et al. Extendedduration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010;153:8-18
7. Goyen M. Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag 2008;4:1-9
8. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC randomized study. Circulation 2005;112:416-22
9. Harlal A, Ojha M, Johnston KW. Vena cava filter performance based on hemodynamics and reported thrombosis and pulmonary embolism patterns. J Vasc Interv Radiol 2007;18:103-15
10. Couch GG, Johnston KW, Ojha M. An in vitro comparison of the hemodynamics of two inferior vena cava filters. J Vasc Surg 2000;31:539-49
11. Leask RL, Johnston KW, Ojha M. Haemodynamic effects of clot entrapment in the TrapEase inferior vena cava filter. J Vasc Interv Radiol 2004;15:485-90
12. Usoh F, Hingorani A, Ascher E, et al. Prospective randomized study comparing the clinical outcomes between inferior vena cava Greenfield and TrapEase filters. J Vasc Surg 2010;52:394-9
13. Karmy-Jones R, Jurkovich GJ, Velmahos GC, et al. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. J Trauma 2007;62:17-24
14. Proctor MC, Greenfield LJ. Form and function of vena cava filters: how do optional filters measure up? Vascular 2008;16:10-6
15. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
16. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
17. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-34
18. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventionalintensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-9
19. Siragusa S, Malato A, Anastasio R, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 2008;112:511-5
20. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355:1780-9
21. Baekgaard N, Broholm R, Just S, et al. Long-term results using catheter-directed thrombolysis in 103 lower limbs with acute iliofemoral venous thrombosis. Eur J Vasc Endovasc Surg 2010;39:112-7
22. Comerota AJ, Throm RC, Mathias SD, et al. Catheterdirected thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg 2000;32:130-7
23. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008;149:698-707
24. Comerota AJ, Grewal N, Martinez J, et al. Post-thrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral DVT. J Vasc Surg 2011 (in press)
25. Comerota AJ, Gale SS. Technique of contemporary iliofemoral and infrainguinal venous thrombectomy. J Vasc Surg 2006;43:185-91
26. Martinez J, Comerota AJ, Kazanjian S, et al. The quantitative benefit of isolated, segmental, pharmacomechanical thrombolysis for iliofemoral DVT. J Vasc Surg 2008;48:1532-7
27. Rutherford RB, Padberg FT Jr, Comerota AJ, et al. Venous severity scoring: an adjunct to venous outcome assessment. J Vasc Surg 2000;31:1307-12
28. Kahn SR, Partsch H, Vedantham S, et al. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009;7:879-83
29. Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004;40:1248-52
30. Brandjes DP, Buller HR, Heijboer H, et al. Randomized trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349:759-62
31. Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the postthrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004;141:249-56
32. Labropoulos N, Volteas N, Leon M, et al. The role of venous outflow obstruction in patients with chronic venous dysfunction. Arch Surg 1997;132:46-51
33. Comerota AJ, Grewal NK, Thakur S, et al. Endovenectomy of the common femoral vein and intraoperative iliac vein recanalization for chronic iliofemoral venous occlusion. J Vasc Surg 2010;52:243-7